Ligand Pharmaceuticals | LGND - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Agenus USD 39.21M 49.82M 2026-03
Amgen USD 2.08B 570M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Baxter International USD 362M 368M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Enviri Corporation USD 233.18M 21.88M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -11.37M 150.72M 2026-06
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Pacira USD 5M 4.43M 2026-03
Pfizer USD -653M 5.84B 2026-06
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 26.52M 3.45M 2026-06